Rekah Pharmaceutical Industry Ltd banner
R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 236 ILS Market Closed
Market Cap: ₪146.3m

Relative Value

The Relative Value of one REKA stock under the Base Case scenario is hidden ILS. Compared to the current market price of 1 236 ILS, Rekah Pharmaceutical Industry Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

REKA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

REKA Competitors Multiples
Rekah Pharmaceutical Industry Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IL
Rekah Pharmaceutical Industry Ltd
TASE:REKA
146.3m ILS 0.5 -10.4 9.9 -65.8
US
Eli Lilly and Co
NYSE:LLY
973.8B USD 14.9 47.2 31.8 33.8
US
Johnson & Johnson
NYSE:JNJ
575.5B USD 6.1 21.5 14.9 18.3
CH
Roche Holding AG
SIX:ROG
278.8B CHF 4.5 29.7 12.6 14.6
CH
Novartis AG
SIX:NOVN
231.7B CHF 5.3 21.3 13.2 16.9
UK
AstraZeneca PLC
LSE:AZN
219.5B GBP 5.2 32.4 15.4 22.6
US
Merck & Co Inc
NYSE:MRK
292.2B USD 4.5 16 10 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.6 9.9 11.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
157.5B USD 2.5 20.3 7.5 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
123.8B USD 2.6 17.5 6.9 8.8
P/E Multiple
Earnings Growth PEG
IL
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Average P/E: 24.4
Negative Multiple: -10.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.2
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
29.7
29%
1
CH
Novartis AG
SIX:NOVN
21.3
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
32.4
38%
0.9
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.3
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IL
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Average EV/EBITDA: 42.3
9.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.8
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
CH
Novartis AG
SIX:NOVN
13.2
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.4
10%
1.5
US
Merck & Co Inc
NYSE:MRK
10
7%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IL
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Average EV/EBIT: 98.4
Negative Multiple: -65.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.8
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
CH
Novartis AG
SIX:NOVN
16.9
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.6
23%
1
US
Merck & Co Inc
NYSE:MRK
11.7
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-6%
N/A